# Weave Bio

> Weave Bio is a San Francisco-based, AI-native software company that automates the regulatory paperwork behind drug development. Its platform ingests preclinical and clinical study data and drafts submission-ready documents - INDs, investigator's brochures, clinical study reports and health-authority responses - in eCTD-ready format, cutting timelines that once took months down to hours while keeping human reviewers in the loop. Founded in 2022, Weave serves biotech, pharma, CROs and regulatory consultants, and raised a $20M Series A in October 2025 to bring total funding to roughly $36M.

- **Founded:** 2022
- **Headquarters:** San Francisco, California, United States
- **Founders:** Brandon Rice (Co-Founder & Chief Product Officer (founding CEO)), Umut Eser (Co-Founder & CTO / Chief AI Officer)
- **Team size:** ~53 employees
- **Products:** The Weave Platform, AutoIND, Submission Builder, HAQ Manager
- **Notable:** Won 'Biotech AI Innovation of the Year' for AutoIND / preclinical IND automation., Raised $20M Series A (Oct 2025), ~$36M total funding., Drafted in ~3 hours what would take human teams ~100 hours in a pharma project.

## Products & services

- **The Weave Platform** — End-to-end AI-native regulatory automation platform covering data organization, authoring, review, publishing and response management with eCTD-formatted templates, real-time collaboration, version control and two-click source traceability.
- **AutoIND** — Automated preparation of preclinical Investigational New Drug (IND) submissions; drafted regulatory documents in ~3 hours that would take humans ~100 hours. Won 'Biotech AI Innovation of the Year.'
- **Submission Builder** — Tooling to assemble and format complete eCTD submissions ready for FDA, EMA and other global authorities.
- **HAQ Manager** — AI and workflow automation to accelerate responses to Health Authority Questions during regulatory review, extending Weave beyond submission prep into the post-submission review phase.

## Achievements

- Won 'Biotech AI Innovation of the Year' for AutoIND / preclinical IND automation.
- Raised $20M Series A (Oct 2025), ~$36M total funding.
- Drafted in ~3 hours what would take human teams ~100 hours in a pharma project.
- Claims 50%+ acceleration of regulatory timelines.
- Secured AI partnership with global CRO Parexel.
- Adopted by public and private biotechs including Recursion and Argenx.

## Latest updates

- **2025-11** — Launched HAQ Manager, extending AI-native automation into the health-authority-question review phase.
- **2025-10** — Closed $20M Series A led by USVP, bringing total funding to ~$36M; plans global expansion into Europe, Japan and Latin America.
- **2025-09** — Announced AI partnership with CRO Parexel to accelerate regulatory submissions.

## Links

- Website: https://www.weave.bio
- LinkedIn: https://www.linkedin.com/company/weavebio
- Twitter/X: https://twitter.com/weave_bio

---

Profile page: https://yespress.io/weave-bio
Published by YesPress — https://yespress.io
Last updated: 2026-07-10